title: [Use of prostacyclin in patients with ischemic stroke. A double-blind method II].
abstract: Thirty patients with acute ischaemic stroke were allocated randomly into a group treated with prostacyclin and a group receiving placebo. The treatment was started 24 to 72 hours after the onset of stroke. Prostacyclin sodium (Wellcome, U.K. or Chinoin, HPR) or its solvent (glycine buffer) were administered intravenously once daily during 2 weeks in 6-hour infusions. Prostacyclin was infused at rates of 2.5-5.0 ng/kg/min. Statistically significant improvement appeared from the second day on in the prostacyclin group, and only from the eighth day on in the placebo group. However, the final improvement was not statistically different between these groups.
authors.affiliation: Z Oddziału Neurologii Szpitala im. J. Dielta w Krakowie.
authors.forename: J
authors.initials: J
authors.lastname: Huczyński
authors.forename: R J
authors.initials: RJ
authors.lastname: Gryglewski
authors.forename: E
authors.initials: E
authors.lastname: Kostka-Trabka
authors.forename: A
authors.initials: A
authors.lastname: Dembińska-Kieć
authors.forename: E
authors.initials: E
authors.lastname: Pykosz-Mazur
authors.forename: W
authors.initials: W
authors.lastname: Sotowska
authors.forename: L
authors.initials: L
authors.lastname: Grodzińska
authors.forename: E
authors.initials: E
authors.lastname: Peczak
authors.forename: K
authors.initials: K
authors.lastname: Bieroń
authors.forename: A
authors.initials: A
authors.lastname: Kedzior
mesh_terms: D000328:Adult; D000368:Aged; D002545:Brain Ischemia / Q000150:complications*; D002544:Cerebral Infarction / Q000188:drug therapy* / Q000209:etiology; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D011464:Epoprostenol / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011465:Prostaglandins, Synthetic / Q000627:therapeutic use*
chemical_list: D011465:Prostaglandins, Synthetic; D011464:Epoprostenol
vernacular_title: Zastosowanie prostacykliny u chorych z udarem niedokrwiennym mózgu. Próba podwójnie ślepa II.